{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T04:48:12Z","timestamp":1787028492692,"version":"build-2736575974"},"reference-count":175,"publisher":"MDPI AG","issue":"23","license":[{"start":{"date-parts":[[2022,11,28]],"date-time":"2022-11-28T00:00:00Z","timestamp":1669593600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Salivary gland malignancies (SGMs) account for less than 5% of new diagnoses in head and neck tumors. If feasible, surgery is the preferred treatment modality. Nevertheless, some malignancies have a tendency of recurrence, with possible distant metastasis. Alternative treatment strategies, such as primary radiation or chemotherapeutics, often present low response rates. As a result, there is an unmet need for novel therapeutic approaches. Nowadays, target-based therapies (e.g., small inhibitors and immunotherapy) are used by the medical oncologist for possible treatment of advanced SGMs. Based on recent published trials, some novel treatments may provide additional disease control for some patients. However, sample sizes are small, the general findings are unsatisfactory, and a lot of uncertainties remain to be elucidated. Nevertheless, research shows that patients do not benefit from blind administration of systemic treatments and therefore a more personalized approach is highly needed. The aim of this review paper is to summarize the most recent advances in the biological understanding and molecular pathways of salivary gland cancers, the association of these pathways with the current treatments used and their implications for more personalized targeted-based therapies.<\/jats:p>","DOI":"10.3390\/ijms232314891","type":"journal-article","created":{"date-parts":[[2022,11,28]],"date-time":"2022-11-28T07:38:49Z","timestamp":1669621129000},"page":"14891","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["The Therapeutic Landscape of Salivary Gland Malignancies\u2014Where Are We Now?"],"prefix":"10.3390","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8089-8601","authenticated-orcid":false,"given":"Robbert","family":"Cleymaet","sequence":"first","affiliation":[{"name":"Department of Oromaxillofacial and Plastic Surgery, Ghent University Hospital, 9000 Ghent, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1335-9966","authenticated-orcid":false,"given":"Tijl","family":"Vermassen","sequence":"additional","affiliation":[{"name":"Department Medical Oncology, University Hospital Ghent, 9000 Ghent, Belgium"},{"name":"Department Basic and Applied Medical Sciences, Ghent University, 9000 Ghent, Belgium"},{"name":"Cancer Research Institute Ghent, 9000 Ghent, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renaat","family":"Coopman","sequence":"additional","affiliation":[{"name":"Department of Oromaxillofacial and Plastic Surgery, Ghent University Hospital, 9000 Ghent, Belgium"},{"name":"Cancer Research Institute Ghent, 9000 Ghent, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hubert","family":"Vermeersch","sequence":"additional","affiliation":[{"name":"Department of Oromaxillofacial and Plastic Surgery, Ghent University Hospital, 9000 Ghent, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stijn","family":"De Keukeleire","sequence":"additional","affiliation":[{"name":"Department Internal Medicine, University Hospital Brussels, 1090 Brussels, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sylvie","family":"Rottey","sequence":"additional","affiliation":[{"name":"Department Medical Oncology, University Hospital Ghent, 9000 Ghent, Belgium"},{"name":"Department Basic and Applied Medical Sciences, Ghent University, 9000 Ghent, Belgium"},{"name":"Cancer Research Institute Ghent, 9000 Ghent, Belgium"},{"name":"Drug Research Unit Ghent, University Hospital Ghent, 9000 Ghent, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,11,28]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.5858\/133.11.1763","article-title":"Update on selected salivary gland neoplasms","volume":"133","author":"McHugh","year":"2009","journal-title":"Arch. Pathol. Lab. Med."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1097\/00001648-199707000-00011","article-title":"Environmental factors and the risk of salivary gland cancer","volume":"8","author":"Ljung","year":"1997","journal-title":"Epidemiology"},{"key":"ref_3","first-page":"58","article-title":"Mucoepidermoid carcinoma of the base of tongue","volume":"35","author":"Mesolella","year":"2015","journal-title":"Acta Otorhinolaryngol. Ital."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1016\/j.jormas.2020.06.003","article-title":"Mucoepidermoid carcinoma. An update and review of the literature","volume":"121","author":"Peraza","year":"2020","journal-title":"J. Stomatol. Oral Maxillofac. Surg."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1002\/hed.2890080309","article-title":"Salivary neoplasms: Overview of a 35-year experience with 2,807 patients","volume":"8","author":"Spiro","year":"1986","journal-title":"Head Neck Surg."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/0002-9610(78)90262-3","article-title":"Mucoepidermoid carcinoma of salivary gland origin: A clinicopathologic study of 367 cases","volume":"136","author":"Spiro","year":"1978","journal-title":"Am. J. Surg."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"3928","DOI":"10.1002\/cncr.26697","article-title":"Prognostic factors in mucoepidermoid carcinoma of the salivary glands","volume":"118","author":"McHugh","year":"2012","journal-title":"Cancer"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1","DOI":"10.14740\/wjon1412","article-title":"Advances in the Treatment of Mucoepidermoid Carcinoma","volume":"13","author":"Sama","year":"2022","journal-title":"World J. Oncol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1007\/s12105-020-01210-7","article-title":"Prognostic Factors and Survival in Adenoid Cystic Carcinoma of the Head and Neck: A Retrospective Clinical and Histopathological Analysis of Patients Seen at a Cancer Center","volume":"15","author":"Moreira","year":"2021","journal-title":"Head Neck Pathol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"S65","DOI":"10.4103\/jomfp.JOMFP_5_16","article-title":"Adenoid cystic carcinoma of palate: Report of a solid variant","volume":"22","author":"Srivastava","year":"2018","journal-title":"J. Oral Maxillofac. Pathol. JOMFP"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1097\/PAS.0000000000000918","article-title":"Predictors of Outcome in Adenoid Cystic Carcinoma of Salivary Glands: A Clinicopathologic Study with Correlation Between MYB Fusion and Protein Expression","volume":"41","author":"Xu","year":"2017","journal-title":"Am. J. Surg. Pathol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"296","DOI":"10.14639\/0392-100X-N1729","article-title":"Adenoid cystic carcinoma. An indolent but aggressive tumour. Part B: Treatment and prognosis","volume":"41","author":"Cantu","year":"2021","journal-title":"Acta Otorhinolaryngol. Ital."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1001\/jamaoto.2015.3930","article-title":"A 20-Year Review of 75 Cases of Salivary Duct Carcinoma","volume":"142","author":"Gilbert","year":"2016","journal-title":"JAMA Otolaryngol. Head Neck Surg."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1002\/cncy.22288","article-title":"Salivary duct carcinoma: Updates in histology, cytology, molecular biology, and treatment","volume":"128","author":"Nakaguro","year":"2020","journal-title":"Cancer Cytopathol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1097\/MOO.0000000000000436","article-title":"Salivary duct carcinoma","volume":"26","author":"Meulemans","year":"2018","journal-title":"Curr. Opin. Otolaryngol. Head Neck Surg."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/S1658-3876(09)50035-0","article-title":"Acinic cell carcinoma of the salivary glands: A literature review","volume":"2","author":"Obeid","year":"2009","journal-title":"Hematol.\/Oncol. Stem Cell Ther."},{"key":"ref_17","unstructured":"Ammad Ud Din, M., and Shaikh, H. (2022). Adenoid Cystic Cancer, StatPearls."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"3945","DOI":"10.1002\/cncr.26740","article-title":"A comparison of the demographics, clinical features, and survival of patients with adenoid cystic carcinoma of major and minor salivary glands versus less common sites within the Surveillance, Epidemiology, and End Results registry","volume":"118","author":"Li","year":"2012","journal-title":"Cancer"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"105370","DOI":"10.1016\/j.oraloncology.2021.105370","article-title":"Differential diagnosis and treatment of salivary secretory carcinoma and acinic cell carcinoma","volume":"119","author":"Pang","year":"2021","journal-title":"Oral Oncol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"2146","DOI":"10.1016\/j.joms.2009.09.064","article-title":"Fine-needle aspiration cytology of salivary gland lesions: A systematic review","volume":"68","author":"Colella","year":"2010","journal-title":"J. Oral Maxillofac. Surg."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.3174\/ajnr.A4247","article-title":"Comparison of fine-needle aspiration and core needle biopsy under ultrasonographic guidance for detecting malignancy and for the tissue-specific diagnosis of salivary gland tumors","volume":"36","author":"Eom","year":"2015","journal-title":"Am. J. Neuroradiol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/j.ejrad.2008.01.027","article-title":"Imaging of salivary gland tumours","volume":"66","author":"Lee","year":"2008","journal-title":"Eur. J. Radiol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1002\/jmri.22091","article-title":"Multiparametric magnetic resonance imaging for the differentiation between benign and malignant salivary gland tumors","volume":"31","author":"Eida","year":"2010","journal-title":"J. Magn. Reson. Imaging"},{"key":"ref_24","first-page":"240","article-title":"Clinical utility of 18F-FDG PET for patients with salivary gland malignancies","volume":"48","author":"Roh","year":"2007","journal-title":"J. Nucl. Med."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1148\/radiology.192.1.8208973","article-title":"Salivary gland tumors: Pretherapy evaluation with PET","volume":"192","author":"Keyes","year":"1994","journal-title":"Radiology"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1200\/JCO.21.00449","article-title":"Management of Salivary Gland Malignancy: ASCO Guideline","volume":"39","author":"Geiger","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.oraloncology.2016.12.007","article-title":"Surgical treatment of salivary malignant tumors","volume":"65","author":"Lombardi","year":"2017","journal-title":"Oral Oncol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.1002\/hed.27062","article-title":"Estimating survival after salvage surgery for recurrent salivary gland cancers: Systematic review","volume":"44","author":"Mannelli","year":"2022","journal-title":"Head Neck"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1038\/s41368-019-0059-9","article-title":"Conservative and functional surgery in the treatment of salivary gland tumours","volume":"11","author":"Yu","year":"2019","journal-title":"Int. J. Oral Sci."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.otc.2015.11.001","article-title":"Diagnosis and Management of Malignant Salivary Gland Tumors of the Parotid Gland","volume":"49","author":"Lewis","year":"2016","journal-title":"Otolaryngol. Clin. North Am."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/MD.0b013e31824125e4","article-title":"Prognosis and outcome of non-Hodgkin lymphoma in primary Sjogren syndrome","volume":"91","author":"Voulgarelis","year":"2012","journal-title":"Medicine"},{"key":"ref_32","first-page":"3781","article-title":"Paclitaxel and carboplatin for recurrent salivary gland malignancies","volume":"20","author":"Airoldi","year":"2000","journal-title":"Anticancer Res."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1097\/COC.0000000000000112","article-title":"Cisplatin+Vinorelbine Treatment of Recurrent or Metastatic Salivary Gland Malignancies (RMSGM): A Final Report on 60 Cases","volume":"40","author":"Airoldi","year":"2017","journal-title":"Am. J. Clin. Oncol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1002\/1097-0142(20010201)91:3<541::AID-CNCR1032>3.0.CO;2-Y","article-title":"Phase II randomized trial comparing vinorelbine versus vinorelbine plus cisplatin in patients with recurrent salivary gland malignancies","volume":"91","author":"Airoldi","year":"2001","journal-title":"Cancer"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1002\/mpo.2950160309","article-title":"Preliminary experience with chemotherapy in advanced salivary gland neoplasms","volume":"16","author":"Belani","year":"1988","journal-title":"Med. Pediatr. Oncol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"2313","DOI":"10.1002\/1097-0142(19881201)62:11<2313::AID-CNCR2820621110>3.0.CO;2-4","article-title":"Cisplatin-based chemotherapy for neoplasms arising from salivary glands and contiguous structures in the head and neck","volume":"62","author":"Creagan","year":"1988","journal-title":"Cancer"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1002\/hed.2880140403","article-title":"Cisplatin-based chemotherapy in advanced adenoid cystic carcinoma of the head and neck","volume":"14","author":"Vermorken","year":"1992","journal-title":"Head Neck"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1200\/JCO.1990.8.6.1056","article-title":"Fluorouracil, doxorubicin, cyclophosphamide, and cisplatin combination chemotherapy in advanced or recurrent salivary gland carcinoma","volume":"8","author":"Dimery","year":"1990","journal-title":"J. Clin. Oncol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"2869","DOI":"10.1002\/1097-0142(19871215)60:12<2869::AID-CNCR2820601203>3.0.CO;2-Y","article-title":"Cyclophosphamide, doxorubicin, and cisplatin combination chemotherapy for advanced carcinomas of salivary gland origin","volume":"60","author":"Dreyfuss","year":"1987","journal-title":"Cancer"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1002\/hed.20327","article-title":"Phase II trial of taxol in salivary gland malignancies (E1394): A trial of the Eastern Cooperative Oncology Group","volume":"28","author":"Gilbert","year":"2006","journal-title":"Head Neck"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/S0964-1955(97)00026-2","article-title":"Cisplatin and 5-fluorouracil for symptom control in advanced salivary adenoid cystic carcinoma","volume":"33","author":"Hill","year":"1997","journal-title":"Oral Oncol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1002\/hed.24933","article-title":"Efficacy and safety of vinorelbine plus cisplatin chemotherapy for patients with recurrent and\/or metastatic salivary gland cancer of the head and neck","volume":"40","author":"Hong","year":"2018","journal-title":"Head Neck"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"719","DOI":"10.4143\/crt.2021.1019","article-title":"A Single-Arm, Prospective, Phase II Study of Cisplatin Plus Weekly Docetaxel as First-Line Therapy in Patients with Metastatic or Recurrent Salivary Gland Cancer","volume":"54","author":"Kim","year":"2022","journal-title":"Cancer Res. Treat."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1002\/cncr.24745","article-title":"A phase 2 study of platinum and gemcitabine in patients with advanced salivary gland cancer: A trial of the NCIC Clinical Trials Group","volume":"116","author":"Laurie","year":"2010","journal-title":"Cancer"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1093\/oxfordjournals.annonc.a010684","article-title":"Cisplatin, doxorubicin and cyclophosphamide in advanced salivary gland carcinoma","volume":"7","author":"Licitra","year":"1996","journal-title":"Ann. Oncol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1874","DOI":"10.1002\/1097-0142(19911101)68:9<1874::AID-CNCR2820680904>3.0.CO;2-S","article-title":"Cisplatin in advanced salivary gland carcinoma. A phase II study of 25 patients","volume":"68","author":"Licitra","year":"1991","journal-title":"Cancer"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1007\/BF00216934","article-title":"Southwest Oncology Group study of mitoxantrone for treatment of patients with advanced adenoid cystic carcinoma of the head and neck","volume":"8","author":"Mattox","year":"1990","journal-title":"Investig. New Drugs"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"948","DOI":"10.3109\/00016489.2016.1170876","article-title":"Combination chemotherapy of carboplatin and paclitaxel for advanced\/metastatic salivary gland carcinoma patients: Differences in responses by different pathological diagnoses","volume":"136","author":"Nakano","year":"2016","journal-title":"Acta Oto-Laryngol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1001\/archotol.1981.00790480015004","article-title":"Cisplatin therapy for adenoid cystic carcinoma","volume":"107","author":"Schramm","year":"1981","journal-title":"Arch. Otolaryngol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1002\/1097-0142(19800801)46:3<452::AID-CNCR2820460305>3.0.CO;2-Z","article-title":"Chemotherapy for adenocystic carcinoma","volume":"46","author":"Tannock","year":"1980","journal-title":"Cancer"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1002\/1097-0142(19870301)59:5<887::AID-CNCR2820590505>3.0.CO;2-8","article-title":"5-Fluorouracil, cyclophosphamide, and vincristine for adenoid cystic carcinoma of the head and neck","volume":"59","author":"Triozzi","year":"1987","journal-title":"Cancer"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"2542","DOI":"10.1016\/j.ejca.2008.08.014","article-title":"Phase II study on gemcitabine in recurrent and\/or metastatic adenoid cystic carcinoma of the head and neck (EORTC 24982)","volume":"44","author":"Locati","year":"2008","journal-title":"Eur. J. Cancer"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1093\/oxfordjournals.annonc.a058665","article-title":"Epirubicin in patients with advanced or recurrent adenoid cystic carcinoma of the head and neck: A phase II study of the EORTC Head and Neck Cancer Cooperative Group","volume":"4","author":"Vermorken","year":"1993","journal-title":"Ann. Oncol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1093\/oxfordjournals.annonc.a010770","article-title":"Phase II study on mitoxantrone in adenoid cystic carcinomas of the head and neck","volume":"7","author":"Verweij","year":"1996","journal-title":"Ann. Oncol."},{"key":"ref_55","first-page":"4092","article-title":"Systemic therapies for salivary gland adenoid cystic carcinoma","volume":"11","author":"Sahara","year":"2021","journal-title":"Am. J. Cancer Res."},{"key":"ref_56","first-page":"956","article-title":"KIT protein expression and analysis of c-kit gene mutation in adenoid cystic carcinoma","volume":"12","author":"Holst","year":"1999","journal-title":"Mod. Pathol."},{"key":"ref_57","first-page":"671","article-title":"Differential expression of vascular endothelial growth factor in high- and low-metastasis cell lines of salivary gland adenoid cystic carcinoma","volume":"34","author":"Kondo","year":"2014","journal-title":"Anticancer Res."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"518","DOI":"10.4143\/crt.2015.093","article-title":"VEGF and Ki-67 Overexpression in Predicting Poor Overall Survival in Adenoid Cystic Carcinoma","volume":"48","author":"Park","year":"2016","journal-title":"Cancer Res. Treat."},{"key":"ref_59","doi-asserted-by":"crossref","unstructured":"Zhang, J., and Peng, B. (2007). In vitro angiogenesis and expression of nuclear factor kappaB and VEGF in high and low metastasis cell lines of salivary gland Adenoid Cystic Carcinoma. BMC Cancer, 7.","DOI":"10.1186\/1471-2407-7-95"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"7334","DOI":"10.1158\/1078-0432.CCR-05-0241","article-title":"Expressions of nuclear factor kappaB, inducible nitric oxide synthase, and vascular endothelial growth factor in adenoid cystic carcinoma of salivary glands: Correlations with the angiogenesis and clinical outcome","volume":"11","author":"Zhang","year":"2005","journal-title":"Clin. Cancer Res."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1002\/(SICI)1096-9896(199604)178:4<429::AID-PATH495>3.0.CO;2-1","article-title":"Immunohistochemical study of overexpression of fibroblast growth factor-1 (FGF-1), FGF-2, and FGF receptor-1 in human malignant salivary gland tumours","volume":"178","author":"Myoken","year":"1996","journal-title":"J. Pathol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"3133","DOI":"10.1158\/1078-0432.CCR-06-2555","article-title":"DNA copy number gains at loci of growth factors and their receptors in salivary gland adenoid cystic carcinoma","volume":"13","author":"Vekony","year":"2007","journal-title":"Clin. Cancer Res."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1097\/00005537-200108000-00011","article-title":"Molecular differences in mucoepidermoid carcinoma and adenoid cystic carcinoma of the major salivary glands","volume":"111","author":"Gibbons","year":"2001","journal-title":"Laryngoscope"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1002\/hed.10104","article-title":"Immunohistochemical study of epidermal growth factor receptor in adenoid cystic carcinoma of salivary gland origin","volume":"24","author":"Vered","year":"2002","journal-title":"Head Neck"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1007\/BF00718645","article-title":"Immunohistochemical expression of epidermal growth factor receptor in salivary gland tumours","volume":"415","author":"Yamada","year":"1989","journal-title":"Virchows. Arch. A"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1517\/14728222.9.4.753","article-title":"The insulin-like growth factor-I receptor as a target for cancer therapy","volume":"9","author":"Baserga","year":"2005","journal-title":"Expert Opin. Ther. Targets"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1158\/1535-7163.MCT-06-0080","article-title":"Disrupting insulin-like growth factor signaling as a potential cancer therapy","volume":"6","author":"Sachdev","year":"2007","journal-title":"Mol. Cancer Ther."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1038\/ncponc0934","article-title":"Mechanisms of disease: Signaling of the insulin-like growth factor 1 receptor pathway\u2014Therapeutic perspectives in cancer","volume":"4","author":"Tao","year":"2007","journal-title":"Nat. Clin. Pract. Oncol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1158\/1078-0432.CCR-06-1297","article-title":"Increased expression of insulin-like growth factor-II messenger RNA\u2013binding protein 1 is associated with tumor progression in patients with lung cancer","volume":"13","author":"Kato","year":"2007","journal-title":"Clin. Cancer Res."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"S45","DOI":"10.1677\/erc.1.01275","article-title":"Growth factor receptor interplay and resistance in cancer","volume":"13","author":"Jones","year":"2006","journal-title":"Endocr. Relat. Cancer"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1002\/ijc.28737","article-title":"The insulin-like growth factor 1 receptor causes acquired resistance to erlotinib in lung cancer cells with the wild-type epidermal growth factor receptor","volume":"135","author":"Suda","year":"2014","journal-title":"Int. J. Cancer"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"10100","DOI":"10.1158\/0008-5472.CAN-06-1684","article-title":"Heterodimerization of insulin-like growth factor receptor\/epidermal growth factor receptor and induction of survivin expression counteract the antitumor action of erlotinib","volume":"66","author":"Morgillo","year":"2006","journal-title":"Cancer Res."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1007\/s11605-011-1504-z","article-title":"Phosphorylated insulin-like growth factor 1 receptor is implicated in resistance to the cytostatic effect of gefitinib in colorectal cancer cells","volume":"15","author":"Yang","year":"2011","journal-title":"J. Gastrointest. Surg."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1002\/ijc.31353","article-title":"A clinicopathological study and prognostic factor analysis of 177 salivary duct carcinoma patients from The Netherlands","volume":"143","author":"Boon","year":"2018","journal-title":"Int. J. Cancer"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"4623","DOI":"10.1158\/1078-0432.CCR-16-0637","article-title":"Comprehensive Molecular Characterization of Salivary Duct Carcinoma Reveals Actionable Targets and Similarity to Apocrine Breast Cancer","volume":"22","author":"Dalin","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1007\/s10147-014-0674-6","article-title":"Clinicopathological significance of androgen receptor, HER2, Ki-67 and EGFR expressions in salivary duct carcinoma","volume":"20","author":"Masubuchi","year":"2015","journal-title":"Int. J. Clin. Oncol."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"2539","DOI":"10.1093\/annonc\/mdx399","article-title":"Comprehensive genomic profiles of metastatic and relapsed salivary gland carcinomas are associated with tumor type and reveal new routes to targeted therapies","volume":"28","author":"Ross","year":"2017","journal-title":"Ann. Oncol."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"1852","DOI":"10.18632\/oncotarget.22927","article-title":"Prognostic and histogenetic roles of gene alteration and the expression of key potentially actionable targets in salivary duct carcinomas","volume":"9","author":"Shimura","year":"2018","journal-title":"Oncotarget"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"59023","DOI":"10.18632\/oncotarget.19812","article-title":"Biomarker immunoprofile in salivary duct carcinomas: Clinicopathological and prognostic implications with evaluation of the revised classification","volume":"8","author":"Takase","year":"2017","journal-title":"Oncotarget"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.humpath.2019.08.009","article-title":"Biomarker immunoprofile and molecular characteristics in salivary duct carcinoma: Clinicopathological and prognostic implications","volume":"93","author":"Santana","year":"2019","journal-title":"Hum. Pathol."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1016\/j.oraloncology.2009.05.635","article-title":"Treatment relevant target immunophenotyping of 139 salivary gland carcinomas (SGCs)","volume":"45","author":"Locati","year":"2009","journal-title":"Oral Oncol."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1309\/RVTP1G0Q727WJUQD","article-title":"Expression of androgen, estrogen, and progesterone receptors in salivary gland tumors: Frequent expression of androgen receptor in a subset of malignant salivary gland tumors","volume":"119","author":"Nasser","year":"2003","journal-title":"Am. J. Clin. Pathol."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/S0070-2153(10)92013-9","article-title":"Notch signaling in solid tumors","volume":"92","author":"Koch","year":"2010","journal-title":"Curr. Top. Dev. Biol."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"905","DOI":"10.2174\/156652406779010830","article-title":"Notch signaling in cancer","volume":"6","author":"Miele","year":"2006","journal-title":"Curr. Mol. Med."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"4276","DOI":"10.1172\/JCI128227","article-title":"Genetic hallmarks of recurrent\/metastatic adenoid cystic carcinoma","volume":"129","author":"Ho","year":"2019","journal-title":"J. Clin. Investig."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1097\/PAS.0000000000000945","article-title":"Diffuse Staining for Activated NOTCH1 Correlates with NOTCH1 Mutation Status and Is Associated with Worse Outcome in Adenoid Cystic Carcinoma","volume":"41","author":"Sajed","year":"2017","journal-title":"Am. J. Surg. Pathol."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"12293","DOI":"10.1073\/pnas.192461099","article-title":"Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade","volume":"99","author":"Iwai","year":"2002","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1002\/jso.24266","article-title":"Programmed death ligand-1 expression is associated with poor disease free survival in salivary gland carcinomas","volume":"114","author":"Mukaigawa","year":"2016","journal-title":"J. Surg. Oncol."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"3158","DOI":"10.1158\/1078-0432.CCR-16-1761","article-title":"PD-L2 Expression in Human Tumors: Relevance to Anti-PD-1 Therapy in Cancer","volume":"23","author":"Yearley","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1158\/2326-6066.CIR-16-0031","article-title":"Immune Profiling of Adenoid Cystic Carcinoma: PD-L2 Expression and Associations with Tumor-Infiltrating Lymphocytes","volume":"4","author":"Sridharan","year":"2016","journal-title":"Cancer Immunol. Res."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1038\/ng.2643","article-title":"The mutational landscape of adenoid cystic carcinoma","volume":"45","author":"Ho","year":"2013","journal-title":"Nat. Genet."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1038\/ng.3502","article-title":"An oncogenic MYB feedback loop drives alternate cell fates in adenoid cystic carcinoma","volume":"48","author":"Drier","year":"2016","journal-title":"Nat. Genet."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"4722","DOI":"10.1158\/1078-0432.CCR-10-0463","article-title":"Comprehensive analysis of the MYB-NFIB gene fusion in salivary adenoid cystic carcinoma: Incidence, variability, and clinicopathologic significance","volume":"16","author":"Mitani","year":"2010","journal-title":"Clin. Cancer Res."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"18740","DOI":"10.1073\/pnas.0909114106","article-title":"Recurrent fusion of MYB and NFIB transcription factor genes in carcinomas of the breast and head and neck","volume":"106","author":"Persson","year":"2009","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_95","first-page":"1579","article-title":"MYB promotes the growth and metastasis of salivary adenoid cystic carcinoma","volume":"54","author":"Xu","year":"2019","journal-title":"Int. J. Oncol."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"2696","DOI":"10.1158\/1535-7163.MCT-05-0228","article-title":"Concomitant inhibition of epidermal growth factor and vascular endothelial growth factor receptor tyrosine kinases reduces growth and metastasis of human salivary adenoid cystic carcinoma in an orthotopic nude mouse model","volume":"5","author":"Younes","year":"2006","journal-title":"Mol. Cancer Ther."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1111\/j.1365-2184.2009.00588.x","article-title":"NF-kappaB promotes iNOS and VEGF expression in salivary gland adenoid cystic carcinoma cells and enhances endothelial cell motility in vitro","volume":"42","author":"Zhang","year":"2009","journal-title":"Cell Prolif."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"7017","DOI":"10.4049\/jimmunol.165.12.7017","article-title":"Activation of MHC class I, II, and CD40 gene expression by histone deacetylase inhibitors","volume":"165","author":"Magner","year":"2000","journal-title":"J. Immunol."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.ijrobp.2019.09.036","article-title":"The Phase 1\/2 ACCEPT Trial: Concurrent Cetuximab and Intensity Modulated Radiation Therapy with Carbon Ion Boost for Adenoid Cystic Carcinoma of the Head and Neck","volume":"106","author":"Adeberg","year":"2020","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"3978","DOI":"10.1200\/JCO.2007.11.8612","article-title":"Phase II study of lapatinib in recurrent or metastatic epidermal growth factor receptor and\/or erbB2 expressing adenoid cystic carcinoma and non\u2013adenoid cystic carcinoma malignant tumors of the salivary glands","volume":"25","author":"Agulnik","year":"2007","journal-title":"J. Clin. Oncol."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"3374","DOI":"10.1002\/cncr.25852","article-title":"A phase 2 trial of bortezomib followed by the addition of doxorubicin at progression in patients with recurrent or metastatic adenoid cystic carcinoma of the head and neck: A trial of the Eastern Cooperative Oncology Group (E1303)","volume":"117","author":"Argiris","year":"2011","journal-title":"Cancer"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1007\/s10637-018-0597-6","article-title":"A multi-arm phase I dose escalating study of an oral NOTCH inhibitor BMS-986115 in patients with advanced solid tumours","volume":"36","author":"Aung","year":"2018","journal-title":"Investig. New Drugs"},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1007\/s12070-018-1442-0","article-title":"Evaluation of Multimodality Management of Adenoid Cystic Carcinoma of the Head and Neck","volume":"71","author":"Bahl","year":"2019","journal-title":"Indian J. Otolaryngol. Head Neck Surg."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1158\/1078-0432.CCR-15-2301","article-title":"A Phase I Clinical Trial and Independent Patient-Derived Xenograft Study of Combined Targeted Treatment with Dacomitinib and Figitumumab in Advanced Solid Tumors","volume":"23","author":"Calvo","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.1093\/annonc\/mdr522","article-title":"A phase II study of sunitinib in recurrent and\/or metastatic adenoid cystic carcinoma (ACC) of the salivary glands: Current progress and challenges in evaluating molecularly targeted agents in ACC","volume":"23","author":"Chau","year":"2012","journal-title":"Ann. Oncol."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1097\/COC.0000000000000429","article-title":"Pembrolizumab for the Treatment of Advanced Salivary Gland Carcinoma: Findings of the Phase 1b KEYNOTE-028 Study","volume":"41","author":"Cohen","year":"2018","journal-title":"Am. J. Clin. Oncol."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"4138","DOI":"10.1158\/1078-0432.CCR-16-2942","article-title":"A Phase II Study of Dovitinib in Patients with Recurrent or Metastatic Adenoid Cystic Carcinoma","volume":"23","author":"Dillon","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.humpath.2019.03.004","article-title":"The repertoire of genetic alterations in salivary duct carcinoma including a novel HNRNPH3-ALK rearrangement","volume":"88","author":"Dogan","year":"2019","journal-title":"Hum. Pathol."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.ejca.2022.05.007","article-title":"Evaluation of pembrolizumab monotherapy in patients with previously treated advanced salivary gland carcinoma in the phase 2 KEYNOTE-158 study","volume":"171","author":"Even","year":"2022","journal-title":"Eur. J. Cancer"},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1007\/s10637-019-00739-x","article-title":"Safety and clinical activity of the Notch inhibitor, crenigacestat (LY3039478), in an open-label phase I trial expansion cohort of advanced or metastatic adenoid cystic carcinoma","volume":"38","author":"Even","year":"2020","journal-title":"Investig. New Drugs"},{"key":"ref_111","doi-asserted-by":"crossref","unstructured":"Feeney, L., Jain, Y., Beasley, M., Donnelly, O., Kong, A., Moleron, R., Nallathambi, C., Rolles, M., Sanghera, P., and Tin, A. (2021). Centralised RECIST Assessment and Clinical Outcomes with Lenvatinib Monotherapy in Recurrent and Metastatic Adenoid Cystic Carcinoma. Cancers, 13.","DOI":"10.3390\/cancers13174336"},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1093\/annonc\/mdy171","article-title":"A phase I dose-escalation and dose-expansion study of brontictuzumab in subjects with selected solid tumors","volume":"29","author":"Ferrarotto","year":"2018","journal-title":"Ann. Oncol."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1093\/annonc\/mdx771","article-title":"A prospective phase II study of combined androgen blockade in patients with androgen receptor-positive metastatic or locally advanced unresectable salivary gland carcinoma","volume":"29","author":"Fushimi","year":"2018","journal-title":"Ann. Oncol."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1016\/j.bjoms.2010.09.013","article-title":"Phase II study of cisplatin and imatinib in advanced salivary adenoid cystic carcinoma","volume":"49","author":"Ghosal","year":"2011","journal-title":"Br. J. Oral Maxillofac. Surg."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"32918","DOI":"10.18632\/oncotarget.16464","article-title":"A phase 2 study of vorinostat in locally advanced, recurrent, or metastatic adenoid cystic carcinoma","volume":"8","author":"Goncalves","year":"2017","journal-title":"Oncotarget"},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1016\/S1368-8375(03)00097-6","article-title":"Herceptin in patients with advanced or metastatic salivary gland carcinomas. A phase II study","volume":"39","author":"Haddad","year":"2003","journal-title":"Oral Oncol."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1038\/bjc.2013.468","article-title":"Cetuximab and platinum-based chemoradio- or chemotherapy of patients with epidermal growth factor receptor expressing adenoid cystic carcinoma: A phase II trial","volume":"109","author":"Hitre","year":"2013","journal-title":"Br. J. Cancer"},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"1902","DOI":"10.1093\/annonc\/mdw287","article-title":"A phase II study of axitinib (AG-013736) in patients with incurable adenoid cystic carcinoma","volume":"27","author":"Ho","year":"2016","journal-title":"Ann. Oncol."},{"key":"ref_119","doi-asserted-by":"crossref","unstructured":"Ho, A.L., Foster, N.R., Zoroufy, A.J., Campbell, J.D., Worden, F., Price, K., Adkins, D., Bowles, D.W., Kang, H., and Burtness, B. (2022). Phase II Study of Enzalutamide for Patients with Androgen Receptor\u2013Positive Salivary Gland Cancers (Alliance A091404). J. Clin. Oncol., online ahead of print.","DOI":"10.1200\/JCO.22.00229"},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"6096","DOI":"10.1200\/JCO.2016.34.15_suppl.6096","article-title":"Phase II study of regorafenib in progressive, recurrent\/metastatic adenoid cystic carcinoma","volume":"34","author":"Ho","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1002\/hed.23664","article-title":"Efficacy of nelfinavir as monotherapy in refractory adenoid cystic carcinoma: Results of a phase II clinical trial","volume":"37","author":"Hoover","year":"2015","journal-title":"Head Neck"},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1200\/JCO.2005.06.125","article-title":"Imatinib mesylate in patients with adenoid cystic cancers of the salivary glands expressing c-kit: A Princess Margaret Hospital phase II consortium study","volume":"23","author":"Hotte","year":"2005","journal-title":"J. Clin. Oncol."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1002\/hed.23647","article-title":"Phase II study of gefitinib in patients with advanced salivary gland cancers","volume":"37","author":"Jakob","year":"2015","journal-title":"Head Neck"},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"5272","DOI":"10.1158\/1078-0432.CCR-21-1061","article-title":"Randomized Phase II Study of Axitinib versus Observation in Patients with Recurred or Metastatic Adenoid Cystic Carcinoma","volume":"27","author":"Kang","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"2612","DOI":"10.1002\/cncr.29401","article-title":"Phase 2 study of dovitinib in patients with metastatic or unresectable adenoid cystic carcinoma","volume":"121","author":"Keam","year":"2015","journal-title":"Cancer"},{"key":"ref_126","doi-asserted-by":"crossref","unstructured":"Kim, D.W., Oh, D.Y., Shin, S.H., Kang, J.H., Cho, B.C., Chung, J.S., Kim, H., Park, K.U., Kwon, J.H., and Han, J.Y. (2014). A multicenter phase II study of everolimus in patients with progressive unresectable adenoid cystic carcinoma. BMC Cancer, 14.","DOI":"10.1186\/1471-2407-14-795"},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"1958","DOI":"10.1002\/cncr.30537","article-title":"Clinical trial of nintedanib in patients with recurrent or metastatic salivary gland cancer of the head and neck: A multicenter phase 2 study (Korean Cancer Study Group HN14-01)","volume":"123","author":"Kim","year":"2017","journal-title":"Cancer"},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1016\/j.annonc.2019.11.018","article-title":"Targeted therapy for advanced salivary gland carcinoma based on molecular profiling: Results from MyPathway, a phase IIa multiple basket study","volume":"31","author":"Kurzrock","year":"2020","journal-title":"Ann. Oncol."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"6001","DOI":"10.1200\/JCO.2019.37.15_suppl.6001","article-title":"Ado-trastuzumab emtansine in patients with HER2 amplified salivary gland cancers (SGCs): Results from a phase II basket trial","volume":"37","author":"Li","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"3670","DOI":"10.1002\/hed.25891","article-title":"Phase II trial with axitinib in recurrent and\/or metastatic salivary gland cancers of the upper aerodigestive tract","volume":"41","author":"Locati","year":"2019","journal-title":"Head Neck"},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"4061","DOI":"10.1200\/JCO.21.00468","article-title":"Abiraterone Acetate in Patients with Castration-Resistant, Androgen Receptor-Expressing Salivary Gland Cancer: A Phase II Trial","volume":"39","author":"Locati","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1002\/cncr.32754","article-title":"Patients with adenoid cystic carcinomas of the salivary glands treated with lenvatinib: Activity and quality of life","volume":"126","author":"Locati","year":"2020","journal-title":"Cancer"},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.ejca.2016.09.022","article-title":"A phase II study of sorafenib in recurrent and\/or metastatic salivary gland carcinomas: Translational analyses and clinical impact","volume":"69","author":"Locati","year":"2016","journal-title":"Eur. J. Cancer"},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1007\/s00280-013-2372-x","article-title":"Phase 1b study of safety, tolerability and efficacy of R1507, a monoclonal antibody to IGF-1R in combination with multiple standard oncology regimens in patients with advanced solid malignancies","volume":"73","author":"Mahadevan","year":"2014","journal-title":"Cancer Chemother. Pharmacol."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.ijrobp.2020.08.018","article-title":"A Randomized Phase 2 Study of Pembrolizumab with or without Radiation in Patients with Recurrent or Metastatic Adenoid Cystic Carcinoma","volume":"109","author":"Mahmood","year":"2021","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.oraloncology.2005.12.026","article-title":"A phase II study of Imatinib for advanced adenoid cystic carcinoma of head and neck salivary glands","volume":"43","author":"Pfeffer","year":"2007","journal-title":"Oral Oncol."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1002\/hed.25020","article-title":"Phase II trial of eribulin mesylate in recurrent or metastatic salivary gland malignancies","volume":"40","author":"Rodriguez","year":"2018","journal-title":"Head Neck"},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1158\/1078-0432.CCR-19-2214","article-title":"A Phase II Trial of Pembrolizumab and Vorinostat in Recurrent Metastatic Head and Neck Squamous Cell Carcinomas and Salivary Gland Cancer","volume":"26","author":"Rodriguez","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"v159","DOI":"10.1093\/annonc\/mdz244","article-title":"METEOR-1: A phase I study of GSK3326595, a first-in-class protein arginine methyltransferase 5 (PRMT5) inhibitor, in advanced solid tumours","volume":"30","author":"Siu","year":"2019","journal-title":"Ann. Oncol."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1200\/JCO.18.00545","article-title":"Phase II Trial of Trastuzumab and Docetaxel in Patients with Human Epidermal Growth Factor Receptor 2\u2013Positive Salivary Duct Carcinoma","volume":"37","author":"Takahashi","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1200\/JCO.18.01859","article-title":"Phase II Study of Lenvatinib in Patients with Progressive, Recurrent or Metastatic Adenoid Cystic Carcinoma","volume":"37","author":"Tchekmedyian","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1002\/hed.23577","article-title":"Phase II trial of sorafenib in advanced salivary adenoid cystic carcinoma of the head and neck","volume":"37","author":"Thomson","year":"2015","journal-title":"Head Neck"},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.ejca.2021.10.033","article-title":"Excessive toxicity of cabozantinib in a phase II study in patients with recurrent and\/or metastatic salivary gland cancer","volume":"161","author":"Uijen","year":"2022","journal-title":"Eur. J. Cancer"},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1093\/annonc\/mdv537","article-title":"Phase II trial of dasatinib for recurrent or metastatic c-KIT expressing adenoid cystic carcinoma and for nonadenoid cystic malignant salivary tumors","volume":"27","author":"Wong","year":"2016","journal-title":"Ann. Oncol."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"17588359211013626","DOI":"10.1177\/17588359211013626","article-title":"Apatinib in patients with recurrent or metastatic adenoid cystic carcinoma of the head and neck: A single-arm, phase II prospective study","volume":"13","author":"Zhu","year":"2021","journal-title":"Ther. Adv. Med. Oncol."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1007\/s00280-012-1847-5","article-title":"Phase I study of chidamide (CS055\/HBI-8000), a new histone deacetylase inhibitor, in patients with advanced solid tumors and lymphomas","volume":"69","author":"Dong","year":"2012","journal-title":"Cancer Chemother. Pharmacol."},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"1614","DOI":"10.1007\/s00259-017-3737-x","article-title":"Prostate-specific membrane antigen PET imaging and immunohistochemistry in adenoid cystic carcinoma-a preliminary analysis","volume":"44","author":"Krijger","year":"2017","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1186\/s13550-021-00866-8","article-title":"First experiences with (177)Lu-PSMA-617 therapy for recurrent or metastatic salivary gland cancer","volume":"11","author":"Willems","year":"2021","journal-title":"EJNMMI Res."},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"2273","DOI":"10.7150\/thno.38501","article-title":"(68)Ga-PSMA-HBED-CC PET\/CT imaging for adenoid cystic carcinoma and salivary duct carcinoma: A phase 2 imaging study","volume":"10","author":"Lutje","year":"2020","journal-title":"Theranostics"},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"2157","DOI":"10.1007\/s11033-021-07033-1","article-title":"EMT in salivary gland tumors: The expression of microRNAs miR-155 and miR-200c is associated with clinical-pathological parameters","volume":"49","author":"Kerche","year":"2022","journal-title":"Mol. Biol. Rep."},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"1618","DOI":"10.1038\/s41379-022-01126-3","article-title":"Activating IGF1R hotspot non-frameshift insertions define a novel, potentially targetable molecular subtype of adenoid cystic carcinoma","volume":"35","author":"Margolis","year":"2022","journal-title":"Mod. Pathol."},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1007\/s11864-022-01001-y","article-title":"Metastatic Adenoid Cystic Carcinoma: Genomic Landscape and Emerging Treatments","volume":"23","author":"Jovanovic","year":"2022","journal-title":"Curr. Treat. Options Oncol."},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"106028","DOI":"10.1016\/j.oraloncology.2022.106028","article-title":"Clinical disease course and survival outcomes following disease recurrence in adenoid cystic carcinoma with and without NOTCH signaling pathway activation","volume":"133","author":"Feeney","year":"2022","journal-title":"Oral Oncol."},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"580141","DOI":"10.3389\/fonc.2020.580141","article-title":"Salivary Gland Carcinoma: Novel Targets to Overcome Treatment Resistance in Advanced Disease","volume":"10","author":"Souza","year":"2020","journal-title":"Front. Oncol."},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1158\/1078-0432.CCR-20-1192","article-title":"Proteogenomic Analysis of Salivary Adenoid Cystic Carcinomas Defines Molecular Subtypes and Identifies Therapeutic Targets","volume":"27","author":"Ferrarotto","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"3960","DOI":"10.1158\/1078-0432.CCR-20-4071","article-title":"Whole-Genome Sequencing of Common Salivary Gland Carcinomas: Subtype-Restricted and Shared Genetic Alterations","volume":"27","author":"Karpinets","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"ref_157","doi-asserted-by":"crossref","unstructured":"Miller, L.E., Au, V., Mokhtari, T.E., Goss, D., Faden, D.L., and Varvares, M.A. (2022). A Contemporary Review of Molecular Therapeutic Targets for Adenoid Cystic Carcinoma. Cancers, 14.","DOI":"10.3390\/cancers14040992"},{"key":"ref_158","doi-asserted-by":"crossref","unstructured":"Mueller, S.K., Haderlein, M., Lettmaier, S., Agaimy, A., Haller, F., Hecht, M., Fietkau, R., Iro, H., and Mantsopoulos, K. (2022). Targeted Therapy, Chemotherapy, Immunotherapy and Novel Treatment Options for Different Subtypes of Salivary Gland Cancer. J. Clin. Med., 11.","DOI":"10.3390\/jcm11030720"},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"3090","DOI":"10.21037\/tcr-20-2530","article-title":"MicroRNAs in head and neck squamous cell carcinoma: A possible challenge as biomarkers, determinants for the choice of therapy and targets for personalized molecular therapies","volume":"10","author":"Vahabi","year":"2021","journal-title":"Transl. Cancer Res."},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"103592","DOI":"10.1016\/j.critrevonc.2022.103592","article-title":"Mutational and immunologic Landscape in malignant Salivary Gland Tumors harbor the potential for novel therapeutic strategies","volume":"170","author":"Witte","year":"2022","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1016\/j.oooo.2021.03.020","article-title":"Detection of novel fusion genes by next-generation sequencing-based targeted RNA sequencing analysis in adenoid cystic carcinoma of head and neck","volume":"132","author":"Shibata","year":"2021","journal-title":"Oral Surg. Oral Med. Oral Pathol. Oral Radiol."},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1001\/jamaoto.2015.3270","article-title":"Role of CRTC1\/MAML2 Translocation in the Prognosis and Clinical Outcomes of Mucoepidermoid Carcinoma","volume":"142","author":"Saade","year":"2016","journal-title":"JAMA Otolaryngol.\u2013Head Neck Surg."},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"3869","DOI":"10.1038\/onc.2013.348","article-title":"Aberrantly activated AREG\u2013EGFR signaling is required for the growth and survival of CRTC1\u2013MAML2 fusion-positive mucoepidermoid carcinoma cells","volume":"33","author":"Chen","year":"2014","journal-title":"Oncogene"},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"e139497","DOI":"10.1172\/jci.insight.139497","article-title":"The CRTC1-MAML2 fusion is the major oncogenic driver in mucoepidermoid carcinoma","volume":"6","author":"Chen","year":"2021","journal-title":"JCI Insight"},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1038\/s41392-020-00388-0","article-title":"Targeting Notch and EGFR signaling in human mucoepidermoid carcinoma","volume":"6","author":"Ni","year":"2021","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"105940","DOI":"10.1016\/j.oraloncology.2022.105940","article-title":"HIF-1alpha induced NID1 expression promotes pulmonary metastases via the PI3K-AKT pathway in salivary gland adenoid cystic carcinoma","volume":"131","author":"Han","year":"2022","journal-title":"Oral Oncol."},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"153620","DOI":"10.1016\/j.prp.2021.153620","article-title":"Sphk1 promotes salivary adenoid cystic carcinoma progression via PI3K\/Akt signaling","volume":"227","author":"Hou","year":"2021","journal-title":"Pathol. Res. Pract."},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"267","DOI":"10.3892\/or.2015.4390","article-title":"Type III TGF-beta receptor inhibits cell proliferation and migration in salivary glands adenoid cystic carcinoma by suppressing NF-kappaB signaling","volume":"35","author":"Xu","year":"2016","journal-title":"Oncol. Rep."},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1111\/imr.12528","article-title":"The ectonucleotidases CD39 and CD73: Novel checkpoint inhibitor targets","volume":"276","author":"Allard","year":"2017","journal-title":"Immunol. Rev."},{"key":"ref_170","doi-asserted-by":"crossref","first-page":"e000186","DOI":"10.1136\/jitc-2019-000186","article-title":"On the mechanism of anti-CD39 immune checkpoint therapy","volume":"8","author":"Allard","year":"2020","journal-title":"J. Immunother. Cancer"},{"key":"ref_171","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1038\/nature08296","article-title":"Nucleotides released by apoptotic cells act as a find-me signal to promote phagocytic clearance","volume":"461","author":"Elliott","year":"2009","journal-title":"Nature"},{"key":"ref_172","doi-asserted-by":"crossref","unstructured":"Bauer, A., Gebauer, N., Knief, J., Tharun, L., Arnold, N., Riecke, A., Steinestel, K., and Witte, H.M. (2022). The expression of the adenosine pathway markers CD39 and CD73 in salivary gland carcinomas harbors the potential for novel immune checkpoint inhibition. J. Cancer Res. Clin. Oncol., online ahead of print.","DOI":"10.21203\/rs.3.rs-1705690\/v1"},{"key":"ref_173","doi-asserted-by":"crossref","first-page":"4383","DOI":"10.7150\/thno.42986","article-title":"The molecular landscape and microenvironment of salivary duct carcinoma reveal new therapeutic opportunities","volume":"10","author":"Alame","year":"2020","journal-title":"Theranostics"},{"key":"ref_174","doi-asserted-by":"crossref","first-page":"105373","DOI":"10.1016\/j.archoralbio.2022.105373","article-title":"Protein markers of primary salivary gland tumors: A systematic review of proteomic profiling studies","volume":"136","author":"Scarini","year":"2022","journal-title":"Arch. Oral Biol."},{"key":"ref_175","doi-asserted-by":"crossref","first-page":"177","DOI":"10.2174\/156652412798889036","article-title":"alphaA- and alphaB-crystallins interact with caspase-3 and Bax to guard mouse lens development","volume":"12","author":"Hu","year":"2012","journal-title":"Curr. Mol. Med."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/23\/23\/14891\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T01:28:29Z","timestamp":1760146109000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/23\/23\/14891"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,28]]},"references-count":175,"journal-issue":{"issue":"23","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["ijms232314891"],"URL":"https:\/\/doi.org\/10.3390\/ijms232314891","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,28]]}}}